Twelve years after : The french national network on rare head and neck tumours (REFCOR)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Rare cancers constitute less than 10% of head and neck cancers and lack sufficient evidence for standardized care. The French Rare Head and Neck Cancer Expert Network (REFCOR) as established a national database to collect data on these rare cancers. This study aims to describe patient and tumour characteristics in this database.
METHODS: Prospective data collection was conducted across multiple centers. Survival analyses were performed using Kaplan Meier method and Log Rank test. Odds ratios were used for comparing proportions.
RESULTS: A total of 7208 patients were included over a period of 10 years. The most frequent histologies were: Not Otherwise Specified (NOS) adenocarcinoma 13 %, adenoid cystic carcinoma 12 %, squamous cell carcinoma of rare locations 10 %, mucoepidermoid carcinoma 9 %, intestinal-type adenocarcinoma (8 %). Tumours were located in sinonasal area (38 %); salivary glands (32 %); oral cavity / oropharynx / nasopharynx (16 %); larynx / hypopharynx (3 %); ears (1 %); others (3 %). Tumours were predominantly classified as T4 (23 %), N0 (54 %), and M0 (62 %). Primary treatment approach involved tumour resection (78 %) and / or radiotherapy (63 %). Patients with salivary gland cancers exhibited better 5-year overall survival (OS) rates (p < 0.05), and lower recurrence rates compared to patients with sinonasal, laryngeal/ hypopharyngeal cancers. No significant differences were observed in the other comparisons. Acinar cell carcinoma demonstrated the best OS while mucous melanoma had the poorest prognosis.
CONCLUSION: Melanoma, carcinoma NOS, and sinonasal undifferenciated carcinoma still have poor prognoses. Efforts are being made, including training and guidelines, to expand network coverage (REFCOR, EURACAN), improve data collection and contribute to personalized therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:151 |
|---|---|
| Enthalten in: |
Oral oncology - 151(2024) vom: 02. Apr., Seite 106762 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gasne, Cassandre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Head and Neck cancers |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oraloncology.2024.106762 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370028856 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370028856 | ||
| 003 | DE-627 | ||
| 005 | 20240408232801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2024.106762 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM370028856 | ||
| 035 | |a (NLM)38513311 | ||
| 035 | |a (PII)S1368-8375(24)00080-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gasne, Cassandre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Twelve years after |b The french national network on rare head and neck tumours (REFCOR) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Rare cancers constitute less than 10% of head and neck cancers and lack sufficient evidence for standardized care. The French Rare Head and Neck Cancer Expert Network (REFCOR) as established a national database to collect data on these rare cancers. This study aims to describe patient and tumour characteristics in this database | ||
| 520 | |a METHODS: Prospective data collection was conducted across multiple centers. Survival analyses were performed using Kaplan Meier method and Log Rank test. Odds ratios were used for comparing proportions | ||
| 520 | |a RESULTS: A total of 7208 patients were included over a period of 10 years. The most frequent histologies were: Not Otherwise Specified (NOS) adenocarcinoma 13 %, adenoid cystic carcinoma 12 %, squamous cell carcinoma of rare locations 10 %, mucoepidermoid carcinoma 9 %, intestinal-type adenocarcinoma (8 %). Tumours were located in sinonasal area (38 %); salivary glands (32 %); oral cavity / oropharynx / nasopharynx (16 %); larynx / hypopharynx (3 %); ears (1 %); others (3 %). Tumours were predominantly classified as T4 (23 %), N0 (54 %), and M0 (62 %). Primary treatment approach involved tumour resection (78 %) and / or radiotherapy (63 %). Patients with salivary gland cancers exhibited better 5-year overall survival (OS) rates (p < 0.05), and lower recurrence rates compared to patients with sinonasal, laryngeal/ hypopharyngeal cancers. No significant differences were observed in the other comparisons. Acinar cell carcinoma demonstrated the best OS while mucous melanoma had the poorest prognosis | ||
| 520 | |a CONCLUSION: Melanoma, carcinoma NOS, and sinonasal undifferenciated carcinoma still have poor prognoses. Efforts are being made, including training and guidelines, to expand network coverage (REFCOR, EURACAN), improve data collection and contribute to personalized therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Head and Neck cancers | |
| 650 | 4 | |a Rare cancer network | |
| 650 | 4 | |a Rare cancers | |
| 650 | 4 | |a Salivary gland cancer | |
| 650 | 4 | |a Sinonasal cancer | |
| 700 | 1 | |a Atallah, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Dauzier, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Thariat, Juliette |e verfasserin |4 aut | |
| 700 | 1 | |a Fakhry, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Verillaud, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Classe, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Vergez, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Moya-Plana, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Costes-Martineau, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Righini, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a de Gabory, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Digue, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Dupin, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrand, François Régis |e verfasserin |4 aut | |
| 700 | 1 | |a Even, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Baujat, Bertrand |e verfasserin |4 aut | |
| 700 | 0 | |a REFCOR members |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral oncology |d 1998 |g 151(2024) vom: 02. Apr., Seite 106762 |w (DE-627)NLM091475074 |x 1879-0593 |7 nnns |
| 773 | 1 | 8 | |g volume:151 |g year:2024 |g day:02 |g month:04 |g pages:106762 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oraloncology.2024.106762 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 151 |j 2024 |b 02 |c 04 |h 106762 | ||